These results suggest that the absence of PPARγ and the loss of the repressor in the VEGF promoter may result in increased VEGF expression, indicating that PPARγ plays an inhibitory role in the HCC cell growth, migration, and angiogenesis; thus, PPARγ may be a therapeutic target for HCC treatment. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.